Treatment of deep articular talus lesions by matrix associated autologous chondrocyte implantation—results at five years
- 364 Downloads
Treatment of focal full-thickness chondral or osteochondral defects of the talus remains a challenge. The aim of this study was to evaluate the postoperative success and the long-term efficacy of matrix associated autologous chondrocyte implantation in these defects.
Matrix associated autologous chondrocyte implantation (MACI) was applied in 22 consecutive patients (mean age 23.9 years) with full-thickness chondral or osteochondral lesions of the talus. The average defect-size was 1.94 cm² (range 1–6). In case of osteochondritis dissecans (n = 13) an autologous bone graft was performed simultaneously. Follow-ups were routinely scheduled up to 63.5 (±7.4) months, consisting of clinical evaluation and magnetic resonance imaging.
The AOFAS score improved significantly from 70.1 to 87.9/92.6/93.5/95.0/95.5 and 95.3 points at three, six, 12, 24, 36 and 63.5 months, respectively. On a visual analogue scale, pain intensity decreased from 5.7 (±2.6) to 0.9 (±0.8) while subjective function increased from 5.3 (±2.3) to 8.9 (±0.9) at final follow-up (each p < 0.001). The Tegner score rose significantly from 2.4 (±1.2) to 4.7 (±0.6). The MOCART score improved from 62.6 (±19.4) at three months to 83.8 (±9.4) at final follow-up. No significant differences were found between lesions caused by osteochondritis dissecans or trauma and between first- or second-line treatments. For all scores, the most benefit was seen within the first 12 months with stable results afterwards. No major complications were noted.
Matrix associated autologous chondrocyte implantation is capable of significant and stable long-term improvement of pain and functional impairment caused by focal full-thickness chondral and osteochondral talus lesions.
KeywordsCartilage Repair Autologous Chondrocyte Implantation Osteochondral Defect Osteochondral Lesion Osteochondritis Dissecans
Conflict of interest
One of the authors has declared a potential conflict of interest: Genzyme Biosurgery provided reimbursement for educational activities (S.A.). The authors did not receive any financial support for the development and preparation of this article.
- 11.Marlovits S, Singer P, Zeller P, Mandl I, Haller J, Trattnig S (2006) Magnetic resonance observation of cartilage repair tissue (MOCART) for the evaluation of autologous chondrocyte transplantation: determination of interobserver variability and correlation to clinical outcome after 2 years. Eur J Radiol 57:16–23PubMedCrossRefGoogle Scholar
- 13.Koulalis D, Schultz W, Heyden M (2002) Autologous chondrocyte transplantation for osteochondritis dissecans of the talus. Clin Orthop Relat Res 395:186–192Google Scholar
- 17.Giannini S, Battaglia M, Buda R, Cavallo M, Ruffilli A, Vannini F (2009) Surgical treatment of osteochondral lesions of the talus by open-field autologous chondrocyte implantation: a 10-year follow-up clinical and magnetic resonance imaging T2-mapping evaluation. Am J Sports Med 37(Suppl 1):112S–118SPubMedCrossRefGoogle Scholar
- 19.Aurich M, Bedi HS, Smith PJ, Rolauffs B, Muckley T, Clayton J, Blackney M (2011) Arthroscopic treatment of osteochondral lesions of the ankle with matrix-associated chondrocyte implantation: early clinical and magnetic resonance imaging results. Am J Sports Med 39:311–319PubMedCrossRefGoogle Scholar
- 23.Lee KT, Lee YK, Young KW, Park SY, Kim JS (2012) Factors influencing result of autologous chondrocyte implantation in osteochondral lesion of the talus using second look arthroscopy. Scand J Med Sci Sports 22(4):510–515Google Scholar
- 25.Niemeyer P, Salzmann G, Schmal H, Mayr H, Sudkamp NP (2011) Autologous chondrocyte implantation for the treatment of chondral and osteochondral defects of the talus: a meta-analysis of available evidence. Knee Surg Sports Traumatol Arthrosc. Oct 30. [Epub ahead of print]Google Scholar